ISRCTN35444083 https://doi.org/10.1186/ISRCTN35444083

Pharmacogenomics of opioids: an investigation of the genetic determinants of variability in analgesic response to opioids

Submission date 30/09/2004	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 30/09/2004	**Overall study status** Completed	[ ] Statistical analysis plan [ ] Results
Last Edited 19/10/2016	**Condition category** Signs and Symptoms	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Julia Riley

Contact details
Palliative Care
Royal Marsden NHS Trust
Fulham Road
Chelsea
London
United Kingdom
SW3 6JJ
+44 (0)20 7352 8171
Julia.Riley@rmh.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0258123628

Study information

Scientific Title
Pharmacogenomics of opioids: an investigation of the genetic determinants of variability in analgesic response to opioids

Study objectives
The primary aim of this research project is to test the hypothesis that inter-subject variability in response to morphine is determined by polymorphisms in the u-opioid receptor gene.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Analgesic response to opioids

Interventions
Randomised, blinded (Phase 2).
Each subject will act as their own control. On visit one, subjects will be randomised to receive either intravenous morphine or intravenous saline (placebo). They will then cross-over to receive placebo or morphine respectively at the second visit.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/10/2003

Completion date
01/10/2005

Eligibility

Key inclusion criteria
Total number RMH patients 100

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
100

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/10/2003

Date of final enrolment
01/10/2005

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

Palliative Care
London
United Kingdom
SW3 6JJ

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Government

Funder Name
The Royal Marsden NHS Trust

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration